Basel, Switzerland – BioVersys AG (SIX: BIOV), a multi-asset, clinical stage biopharmaceutical company focused on research and development of novel antibacterial products for serious life-threatening infections caused by multi-drug resistant (MDR) bacteria, announced today that management will present a corporate overview at the H.C. Wainwright 28th Annual Global Investment Conference, held on September 14-16, 2026 in New York City, NY.
The presentation is scheduled for September 16, 2026, from 12:30 PM to 1:00 PM ET at the Kennedy II room (4th Floor) of the Lotte New York Palace. Hernan Levett, Chief Financial Officer of BioVersys, will deliver the presentation. Additionally, Dr. Marc Gitzinger, Chief Executive Officer, will provide an on-demand presentation beginning September 11, 2026, at 7:00 AM ET, with a replay available for 90 days. The webcast can be accessed through the H.C. Wainwright platform or via the BioVersys website in the investor section.
The participation of BioVersys at this prominent investment conference underscores the company's commitment to advancing its pipeline of antibacterial products aimed at addressing the growing global threat of antimicrobial resistance (AMR). The company's presence provides an opportunity to engage with investors and highlight its progress and future milestones.
BioVersys is developing innovative therapies designed to overcome resistance mechanisms and block virulence production in harmful bacteria. Its two internal technology platforms, TRIC and Ansamycin Chemistry, enable the development of candidates that directly target the pathogenesis of bacteria, addressing high unmet medical needs in the antimicrobial and microbiome fields. The most advanced programs include BV100, a Phase 3 candidate for nosocomial infections caused by Acinetobacter baumannii, and alpibectir, a Phase 2 candidate for tuberculosis developed in collaboration with GlaxoSmithKline (GSK) and a consortium including the University of Lille, France.
The announcement comes at a critical time when antimicrobial resistance is escalating worldwide, with limited new treatments in development. BioVersys' innovative approach and clinical progress could potentially offer new options for patients with life-threatening resistant infections, which is a significant public health concern. The company's participation in the H.C. Wainwright conference may attract potential investors and partners, supporting the advancement of its pipeline.
BioVersys' CEO and CFO will be available for one-on-one meetings with registered attendees during the conference. Interested parties can request meetings through their H.C. Wainwright representatives.
For more information about BioVersys and its programs, visit the company's website at www.bioversys.com.
